Skip to main content
. 2023 May 31;619(7968):160–166. doi: 10.1038/s41586-023-06123-3

Extended Data Fig. 5. Selective inhibition of oncogenic signaling driven by various KRAS mutants.

Extended Data Fig. 5

Extracts from cell lines treated with the KRAS inhibitor were subjected to RBD pull-down and immunoblotting to determine the effect on KRAS and ERK signaling activation. WT: wild-type, UAWT: upstream activated wild-type. Co-occurring alterations in select other genes are shown. The data in Fig. 4a are densitometric quantifications of the immunoblots shown here.